Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|3|336-348

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.3, 2015-08, pp. : 336-348

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 41-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 820-823

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 720-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 202-209

John Wiley & Sons Inc

Access to resources Recommend Favorite

Very Low Doses of Thalidomide as Single Agent in Relapsed/Refractory Multiple Myeloma

By  

Acta Haematologica, Vol. 116, Iss. 1, 2006-07 ,pp. : 70-71

Karger

Access to resources Recommend Favorite